Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints

2018124 citationsJournal Articlehybrid Open Access

Authors

R. Meier · Swedish Medical Center

D. Blöch · Stanford University

C. Cotrutz · Swedish Medical Center

Alan Beckman · Central Baptist Hospital

G. Henning · Trinity Health Michigan

S.A. Woodhouse · Community Cancer Center

Shirnett Williamson ·

Abstract

Dose-escalated prostate SBRT was administered with minimal toxicity in this multi-institutional study. Relapse rates compared favorably with historical controls. SBRT is a suitable option for LR and IR prostate cancer.

Topics & Keywords

Prostate Cancer Diagnosis and Treatment Advanced Radiotherapy Techniques Prostate Cancer Treatment and Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: International Journal of Radiation Oncology*Biology*Physics

Volume 102, Issue 2, pp. 296-303

DOI: 10.1016/j.ijrobp.2018.05.040

Field-Weighted Citation Impact: 10.45